乳酸左氧氟沙星与头孢呋辛钠治疗下呼吸道感染临床对照观察  

Clinical trial of levofloxacin lactate versus cefuroxime in combating lower respiratory tract infections

作　　者：张树才[1] 袁辉[1] 杨新杰[1] 王群会[1] 

机构地区：[1]北京市结核病胸部肿瘤研究所

出　　处：《中国抗生素杂志》1999年第4期312-314,共3页Chinese Journal of Antibiotics

摘　　要：为了解新一代国产乳酸左氧氟沙星注射液治疗成人下呼吸道感染的疗效及安全性，我们将９０例患者随机分成两组，分别给予乳酸左氧氟沙星４００ｍｇ／ｄ或头孢呋辛钠３．０ｇ／ｄ治疗，疗程７～１４ｄ。结果显示：乳酸左氧氟沙星治疗痊愈率６６．７％，有效率９３．３％，细菌清除率９３．３％，其临床疗效均高于头孢呋辛钠组，但差别无显著性（Ｐ＞０．０５）；乳酸左氧氟沙星不良反应发生率为４．４％，且大多轻微，患者可耐受。结论：对中重度下呼吸道感染患者，特别是病原菌尚未确定的病人，给予乳酸左氧氟沙星治疗是有效且安全的首选方案。To evaluate the efficacy and safety of domestic levofloxacin lactate injection, 90 patients with lower respiratory tract infections were divided into 2 random groups and treated with levofloxacin 400mg/day or cefuroxime 3.0g/day for 7￣14 days respectively. Results showed that the total cure rate, effective rate and the bacterial clearance rate were 66.7%, 93.3% and 93.3% respectively. The clinical efficacy was higher in levofloxacin group than cefuroxime group, but no significant difference was found between the two groups ( P >0.05). The side effects rate was 4.4% in levofloxacin group. The adverse events were generally mild and well tolerated. So we come to a conclusion that before we find the pathogenic bacteria, it is safe and effective to choose levofloxacin lactate treating the moderate and/or, serious patients with lower respiratory tract infections in clinical application.

关 键 词：乳酸左氧氟沙星 头孢呋辛钠 下呼吸道感染 

分 类 号：R560.5[医药卫生—呼吸系统] R978.1[医药卫生—内科学]